|
|
||||||||
Department of Clinical Physiology and Nuclear Medicine, Medical Department B and The Cardiac Transplant Group, Rigshospitalet, University of Copenhagen, Denmark
Correspondence: For correspondence or reprints contact: Morten Folke, MD, Department of Clinical Physiology and Nuclear Medicine, Rigshoepitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
ABSTRACT
Recent studies suggest that cardiac uptake of 111In-labeled antimyosin monoclonal antibody may be estimated semiquantitatively by calculating a heart-to-lung activity ratio, with pulmonary uptake serving as a reference region. Methods: We obtained 96 111In-antimyosin scintigraphs to monitor rejection occurrence after heart transplantation in 26 patients. Results: On five scintigraphs, the count rate density in ROIs over the lungs was markedly higher (mean 53% higher) than that in the immediately preceding and following scintigraphs, whereas the activity in the heart was essentially unchanged. Four of these scintigraphs coincided with ongoing pulmonary infection and the fifth with an occurrence of a high anti-CMV titer. Conclusion: The mechanism of apparent nonspecific antimyosin accumulation in the lungs is uncertain, although increased capillary permeability may be one possibility. Attention should be given to activity in the lungs if this activity is used as a reference in studies of 111In-antimyosin uptake in the heart.
Key Words: cardiac transplantation 111In-antimyosin Fab fragment pulmonary uptake
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |